Osteoblast‐specific EGFR deletion also led to reduced pRSK2, decreased pCREB and less c‐Fos‐positive cells in OS, as shown by IHC (Fig 3C) and Western blot analysis of bone tumors from 6‐ to 7‐month‐old mice (Fig EV2F). This evidence concerns the gene FOS and bone neoplasm.